Forest licenses Mylan's nebivolol
Executive Summary
Forest Laboratories has licensed exclusive US and Canadian rights to Mylan's beta blocker nebivolol, which is already approved and marketed in various territories outside North America for hypertension. Mylan originally acquired rights to the candidate (then in Phase II) in 2001 from J&J's Janssen subsidiary, which agreed to the sublicense.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice